SLS today
$8.10+$0.07 (+0.87%)close Nov 13, 2026Trend
DailyUptrend (confirmed)
4 hourStrong Bearish
1 hourExpanding
15 minStrong Bearish
5 minStrong Bearish
Daily trend turns down below $7.07
Key levels
Resistance$9.75
Resistance$8.13
Support$7.14
Support$4.83
Latest news & SEC filings
EarningsSELLAS Life Sciences reports Q3 EPS of $(0.05), matching estimates
NewsSolaris Resources reports progress at its Monja copper-gold project
EarningsSELLAS Life Sciences Posts Q3 2026 Results, Business Update
All SLS news →About SELLAS Life Sciences
SELLAS Life Sciences is a clinical-stage biopharmaceutical company developing treatments for cancer. Its lead candidate, galinpepimut-S, is a peptide immunotherapy aimed at the WT1 protein found in many tumor types, studied mainly in acute myeloid leukemia. A second candidate, SLS009, is an oral CDK9 inhibitor being tested in blood cancers and some solid tumors. The company operates in the United States and licenses rights in Greater China to a partner.
Based on the company's 10-K filed Mar 19, 2026.
Nasdaq · Healthcare
SELLAS Life Sciences Group, Inc. (SLS)
What Is the Price Target for SLS?
SEPT Low Target
$0.00
SEPT Mid Target
$0.00
SEPT High Target
$0.00
Analyst Consensus
$0.00
Is SLS a Buy or Sell Right Now?
Thesis
- •Revenue growing -86.8% YoY with UNKNOWN trend — consistent growth.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for SLS.
Start Free Trial →Is SLS Overvalued or Undervalued?
Valuation Verdict
OVERVALUED
Methods Used
P/B
Fair Value
$1.84
12
Moat Score
NONE
3/9
Piotroski Score
68.7
Altman Z-Score
What Is Smart Money Doing with SLS?
Insider Signal
NEUTRAL
0 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →SLS Growth Story
Revenue YoY
-86.8%
3yr Revenue CAGR
N/A%
EPS Growth YoY
50%
FCF Growth YoY
N/A%
Revenue Trend
UNKNOWN
Dark Pool Trades for SLS
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for SLS, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 19:19:44 | $8.10 | 3,600 | $$29K | SELL |
| 19:18:35 | $8.06 | 1,908 | $$15K | SELL |
| 19:18:30 | $8.07 | 1,000 | $$8K | SELL |
| 19:18:28 | $8.08 | 1,000 | $$8K | BUY |
| 19:18:00 | $8.07 | 4,116 | $$33K | MIDPOINT |
5 dark pool trades shown · $$94K preview volume
Real-time institutional flow, block trades, and net positioning
Options Flow for SLS
PREVIEWSEPT Investing provides real-time options flow tracking for SLS, including unusual sweep detection, block trades, and dealer positioning. Each trade shows strike, expiry, premium, implied volatility, and greek values for informed decision-making.
| Type | Strike | Expiry | DTE | Premium | Size | Trade |
|---|---|---|---|---|---|---|
| PUT | $4 | Jan 15 | 63 | $$1870 | 11 | SWEEP |
| PUT | $6 | Nov 20 | 7 | $$372 | 4 | SWEEP |
| PUT | $4 | Jan 15 | 63 | $$672 | 4 | SWEEP |
| PUT | $4 | Dec 4 | 21 | $$5850 | 39 | SWEEP |
| PUT | $7.5 | Nov 20 | 7 | $$150 | 1 | SWEEP |
5 options trades shown · 0% calls
Unusual activity, GEX levels, max pain, and dealer positioning
What Traders Are Saying About SLS
2 postsSEPT Investing hosts an active community of 3,500+ traders sharing real-time analysis, trade setups, and market discussion for SLS. Join verified traders discussing price action, dark pool alerts, options flow, and AI-powered market intelligence.
$SLS posted Q3 2026 results and a business update 📄
Zone Setup -- $SLS (SELLAS Life Sciences Group, Inc.) Price: $7.53 | Zone: $6.96 to $9.51 Conviction: HIGH Near support (22% of range) — reversal watch. Earnings: EPS_BEAT. Earnings beat: EPS_BEAT
Join 3,500+ traders discussing SLS in real-time
Trade ideas, setups, dark pool alerts, and AI-powered analysis
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for SELLAS Life Sciences Group, Inc. (SLS) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →SLS — frequently asked questions
What is SLS stock price today?
SELLAS Life Sciences Group, Inc. (SLS) is at $8.10, up 0.87% (+$0.07) at the Nov 13, 2026 close.
Why is SLS stock moving today?
Latest SLS news — Nov 13, 2026: SELLAS Life Sciences reports Q3 EPS of $(0.05), matching estimates · Nov 13, 2026: Solaris Resources reports progress at its Monja copper-gold project
What do analysts rate SLS?
Analyst ratings for SLS: 2 Buy, 0 Hold, 0 Sell — consensus Buy.
Did SLS beat earnings?
SLS last reported on Aug 11, 2026: EPS -$0.05 vs -$0.04 expected — a miss of 11.1%.
Does SLS pay a dividend?
SLS does not currently pay a dividend.
What are SLS support and resistance levels?
Support: $7.14, $4.83, $3.46. Resistance: $8.13, $9.75, $10.71.
What are insiders doing with SLS?
Insider activity: NEUTRAL, 0 buys and 0 sells in the last 90 days.
What is the latest news on SLS?
Nov 13, 2026: SELLAS Life Sciences reports Q3 EPS of $(0.05), matching estimates · Nov 13, 2026: Solaris Resources reports progress at its Monja copper-gold project · Nov 12, 2026: SELLAS Life Sciences Posts Q3 2026 Results, Business Update